JP2012521217A5 - - Google Patents

Download PDF

Info

Publication number
JP2012521217A5
JP2012521217A5 JP2012502150A JP2012502150A JP2012521217A5 JP 2012521217 A5 JP2012521217 A5 JP 2012521217A5 JP 2012502150 A JP2012502150 A JP 2012502150A JP 2012502150 A JP2012502150 A JP 2012502150A JP 2012521217 A5 JP2012521217 A5 JP 2012521217A5
Authority
JP
Japan
Prior art keywords
antibody
composition
antigen
binding fragment
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012502150A
Other languages
English (en)
Japanese (ja)
Other versions
JP5830460B2 (ja
JP2012521217A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/028200 external-priority patent/WO2010111198A1/en
Publication of JP2012521217A publication Critical patent/JP2012521217A/ja
Publication of JP2012521217A5 publication Critical patent/JP2012521217A5/ja
Application granted granted Critical
Publication of JP5830460B2 publication Critical patent/JP5830460B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012502150A 2009-03-23 2010-03-23 癌および線維性疾患を治療する化合物、組成物、および方法 Expired - Fee Related JP5830460B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16234809P 2009-03-23 2009-03-23
US61/162,348 2009-03-23
PCT/US2010/028200 WO2010111198A1 (en) 2009-03-23 2010-03-23 Compounds compositions and methods of treating cancer and fibrotic diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015159597A Division JP2016034945A (ja) 2009-03-23 2015-08-12 癌および線維性疾患を治療する化合物、組成物、および方法

Publications (3)

Publication Number Publication Date
JP2012521217A JP2012521217A (ja) 2012-09-13
JP2012521217A5 true JP2012521217A5 (enExample) 2013-05-09
JP5830460B2 JP5830460B2 (ja) 2015-12-09

Family

ID=42288813

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012502150A Expired - Fee Related JP5830460B2 (ja) 2009-03-23 2010-03-23 癌および線維性疾患を治療する化合物、組成物、および方法
JP2015159597A Pending JP2016034945A (ja) 2009-03-23 2015-08-12 癌および線維性疾患を治療する化合物、組成物、および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015159597A Pending JP2016034945A (ja) 2009-03-23 2015-08-12 癌および線維性疾患を治療する化合物、組成物、および方法

Country Status (8)

Country Link
US (3) US8444983B2 (enExample)
EP (1) EP2411413B1 (enExample)
JP (2) JP5830460B2 (enExample)
CN (2) CN102378766A (enExample)
CA (1) CA2753388C (enExample)
IL (2) IL215061A0 (enExample)
SG (1) SG174367A1 (enExample)
WO (1) WO2010111198A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8444983B2 (en) 2009-03-23 2013-05-21 Quark Pharmaceuticals, Inc. Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
JP2015509085A (ja) * 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドＱｂｉ Ｅｎｔｅｒｐｒｉｓｅｓ Ｌｔｄ． 治療剤および診断剤の選択的送達のためのｅｎｄｏ１８０を標的とする粒子
US20160102127A1 (en) * 2013-05-27 2016-04-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Targeted modulation of macrophages
US9572832B2 (en) * 2013-08-29 2017-02-21 Holy Stone Healthcare Co., Ltd. Compound of glycosaminoglycan and its fabrication method as well as application
TWI731535B (zh) 2014-03-21 2021-06-21 美商艾伯維有限公司 抗-egfr抗體及抗體藥物結合物
WO2015179239A1 (en) * 2014-05-17 2015-11-26 University Of Rochester Compositions and methods to inhibit estrogen receptor beta for the treatment of renal cell carcinoma
AU2015313268B2 (en) * 2014-09-08 2018-12-20 National Cancer Center Cancer-cell-specific antibody, anticancer agent, and cancer testing method
KR20260021643A (ko) * 2016-02-05 2026-02-13 릭스하스피탈렛 uPARAP을 표적으로 하는 항체-약물 접합체
AU2017277914A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
RS61828B1 (sr) 2016-06-08 2021-06-30 Abbvie Inc Anti-b7-h3 antitela i antitelske konjugacije lekova
JP2019526529A (ja) 2016-06-08 2019-09-19 アッヴィ・インコーポレイテッド 抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
CN109641962A (zh) 2016-06-08 2019-04-16 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
US11584932B2 (en) 2016-11-01 2023-02-21 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
JP7350313B2 (ja) 2016-12-16 2023-09-26 ブルーフィン バイオメディシン， インコーポレイテッド 抗ｃｕｂドメイン含有タンパク質１（ｃｄｃｐ１）抗体、抗体薬物コンジュゲート、およびその使用方法
EP3612567B1 (en) 2017-04-19 2024-09-11 Bluefin Biomedicine, Inc. Anti-vtcn1 antibodies and antibody drug conjugates
JP7657440B2 (ja) 2017-06-12 2025-04-07 ブルーフィン バイオメディシン， インコーポレイテッド 抗－ｉｌ１ｒａｐ抗体および抗体薬物コンジュゲート
JP7232453B2 (ja) * 2017-09-15 2023-03-03 学校法人杏林学園 糖尿病網膜症、白内障及び／又は腎症モデル実験動物
JP7674354B2 (ja) * 2019-12-05 2025-05-09 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 肝線維症および線維症に関連する他の疾患に対するエキソソームベースの療法
WO2021262919A2 (en) 2020-06-26 2021-12-30 The Research Foundation For The State University Of New York 5-halouracil-modified micrornas and their use in the treatment of cancer
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
EP4363447A1 (en) 2021-06-29 2024-05-08 Rigshospitalet Antibody-drug conjugates comprising humanized antibodies targeting urokinase type plasminogen activator receptor associated protein (uparap)
TW202434231A (zh) 2022-12-28 2024-09-01 丹麥商阿德森多私人有限公司 包含依喜替康衍生物之靶向uPARAP的抗體-藥物結合物
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
WO2025126157A1 (en) 2023-12-15 2025-06-19 Advesya Anti-il-1rap binding domains and antibody-drug conjugates thereof
WO2025141153A1 (en) * 2023-12-29 2025-07-03 Oncomatryx Biopharma, S.L. Endo180 targeted antibody-drug conjugates
EP4578463A1 (en) * 2023-12-29 2025-07-02 Oncomatryx Biopharma, S.L. Endo-180 targeted antibody-drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL81370A (en) * 1986-02-07 1991-06-30 Genetic Systems Corp Pharmaceutical and diagnostic compositions comprising a plurality of human monoclonal antibodies for the treatment of bacterial diseases,methods for the preparation of the compositions and antibodies and kits containing said compositions
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
US5773268A (en) * 1994-11-09 1998-06-30 Cedars-Sinai Medical Center Chromosome 21 gene marker, compositions and methods using same
ZA973051B (en) 1996-04-24 1998-10-12 Genentech Inc Type c lectins
US6117977A (en) 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
US20050042647A1 (en) 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6251666B1 (en) 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US6077508A (en) 1998-03-23 2000-06-20 American Diagnostica Inc. Urokinase plasminogen activator receptor as a target for diagnosis of metastases
EP1165784A2 (en) 1999-03-31 2002-01-02 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; "orfx"
AU763162B2 (en) 1999-04-13 2003-07-17 Wilex Ag Diagnostic and therapeutic use of antibodies against the urokinase receptor
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
WO2001029058A1 (en) 1999-10-15 2001-04-26 University Of Massachusetts Rna interference pathway genes as tools for targeted genetic interference
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
PT1309726E (pt) 2000-03-30 2010-03-08 Whitehead Biomedical Inst Mediadores de interferência por rna específicos de sequência de rna
KR100909681B1 (ko) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
JP4537057B2 (ja) 2001-08-14 2010-09-01 テルアビブ・ユニバーシティ・フューチャー・テクノロジー・デベロップメント・エルピー 脂質化グリコサミノグリカン粒子ならびに診断及び処置のための薬物及び遺伝子送達におけるその使用
CN1608133A (zh) 2001-10-26 2005-04-20 里伯药品公司 双链核糖核酸用于治疗正(+)链rna病毒感染的用途
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
US7795422B2 (en) 2002-02-20 2010-09-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
BRPI0313202A8 (pt) 2002-08-05 2016-08-16 Atugen Ag Formas adicionais para interferir com as moléculas de rna
WO2004014933A1 (en) 2002-08-07 2004-02-19 University Of Massachusetts Compositions for rna interference and methods of use thereof
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
WO2004100759A2 (en) * 2003-05-19 2004-11-25 Quark Biotech, Inc. Endo 180 receptor for diagnosis and treatment
US7842800B2 (en) 2004-04-02 2010-11-30 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof
EP1776092B1 (en) 2004-07-13 2014-06-25 Ramot at Tel-Aviv University Ltd. Lipidated glycoprotein particles and methods of use
CA2576925C (en) 2004-08-16 2013-12-10 The Cbr Institute For Biomedical Research, Inc. Method of delivering rna interference and uses thereof
JP2008519076A (ja) 2004-11-02 2008-06-05 テルアビブ ユニバーシティ フューチャー テクノロジー デベロップメント エル．ピー． 脂質化グリコサミノグリカン粒子中の水不溶性又は水難溶性薬物の処方、並びに診断及び治療のためのこれらの使用
WO2008020435A2 (en) 2006-08-15 2008-02-21 Quark Pharmaceuticals, Inc Compositions and methods for treatment of mood disorders
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US20100292301A1 (en) 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
WO2008109105A2 (en) * 2007-03-06 2008-09-12 Flagship Ventures Methods and compositions for improved therapeutic effects with sirna
WO2009044392A2 (en) 2007-10-03 2009-04-09 Quark Pharmaceuticals, Inc. Novel sirna structures
EP2259775B1 (en) * 2008-02-27 2015-07-22 Ramot at Tel-Aviv University Ltd. System for delivery of protein in insoluble fibrillar form
US8444983B2 (en) 2009-03-23 2013-05-21 Quark Pharmaceuticals, Inc. Composition of anti-ENDO180 antibodies and methods of use for the treatment of cancer and fibrotic diseases
CA2776568A1 (en) 2009-11-26 2011-06-03 Quark Pharmaceuticals, Inc. Sirna compounds comprising terminal substitutions

Similar Documents

Publication Publication Date Title
JP2012521217A5 (enExample)
JP7458399B2 (ja) 抗クローディン抗体及びそれらの使用
TWI853077B (zh) 新型抗ｃｄ３９抗體
JP2012121878A5 (enExample)
JP2017526339A5 (enExample)
RU2020120539A (ru) Композиции для ингибирования masp-2-зависимой активации комплемента
JP2012034692A5 (enExample)
JP2017507936A5 (enExample)
RU2012137515A (ru) Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
JP2017519501A5 (enExample)
JP2012100675A5 (enExample)
JP2016512425A5 (enExample)
JP2009225799A5 (enExample)
JP2014039548A5 (enExample)
JP2010511388A5 (enExample)
JP2012510461A5 (enExample)
JP2010533498A5 (enExample)
JP2010523541A5 (enExample)
JP2013121353A5 (enExample)
JP2009521206A5 (enExample)
JP2018502060A5 (enExample)
JP2015527319A5 (enExample)
JP2011509245A5 (enExample)
JP2016116536A5 (enExample)
JP2012100677A5 (enExample)